167 related articles for article (PubMed ID: 34551037)
1. Pembrolizumab induced steroid resistant immune mediated colitis and concurrent Clostridioides difficile infection.
Preda CM; Marin RI; Becheanu G; Neacsu F; Manuc T; Manuc M
J Gastrointestin Liver Dis; 2021 Sep; 30(3):411-413. PubMed ID: 34551037
[No Abstract] [Full Text] [Related]
2. Cascade of immunologic adverse events related to pembrolizumab treatment.
Dhenin A; Samartzi V; Lejeune S; Seront E
BMJ Case Rep; 2019 Jun; 12(6):. PubMed ID: 31167767
[TBL] [Abstract][Full Text] [Related]
3. Did Clostridioides difficile testing and infection rates change during the COVID-19 pandemic?
Hawes AM; Desai A; Patel PK
Anaerobe; 2021 Aug; 70():102384. PubMed ID: 34029702
[TBL] [Abstract][Full Text] [Related]
4. Clostridioides difficile from intracardiac vegetation.
Chaudhry R; Khullar S; Arif N; Sagar T; Meena D; Kumar Chowdhury U
Anaerobe; 2021 Jun; 69():102350. PubMed ID: 33610766
[TBL] [Abstract][Full Text] [Related]
5. Need for clinicopathologic correlation of Clostridium difficile colitis in view of molecular diagnosis.
Guarner J; Kraft CS
Clin Infect Dis; 2012 Jan; 54(1):156. PubMed ID: 22187416
[No Abstract] [Full Text] [Related]
6. Diagnostic Modality of Clostridioides difficile Infection Predicts Treatment Response and Outcomes in Inflammatory Bowel Disease.
Gupta A; Wash C; Wu Y; Sorrentino D; Nguyen VQ
Dig Dis Sci; 2021 Feb; 66(2):547-553. PubMed ID: 32207033
[TBL] [Abstract][Full Text] [Related]
7. An unknown reaction to pembrolizumab: giant cell arteritis.
Micaily I; Chernoff M
Ann Oncol; 2017 Oct; 28(10):2621-2622. PubMed ID: 28633343
[No Abstract] [Full Text] [Related]
8. Diagnosis and Treatment of Clostridioides (Clostridium) difficile Infection in Adults in 2020.
Rao K; Malani PN
JAMA; 2020 Apr; 323(14):1403-1404. PubMed ID: 32150234
[No Abstract] [Full Text] [Related]
9. Pembrolizumab-induced immune-mediated fatal colitis with concurrent giardia infection.
Sisman G; Barbur E; Saka D; Erdamar Cetin S
Cancer Immunol Immunother; 2021 Aug; 70(8):2385-2388. PubMed ID: 33481043
[TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis.
Kian W; Zemel M; Elobra F; Sharb AA; Levitas D; Assabag Y; Alguayn F; Yakobson A; Rouvinov K; Fuchs L
Anticancer Drugs; 2022 Jan; 33(1):e738-e740. PubMed ID: 34321417
[TBL] [Abstract][Full Text] [Related]
11. Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus.
Jono M; Kinehara Y; Utsu Y; Tamura Y; Koseto M; Murakami T; Uota A; Ninomiya R; Komo S; Sumitani S; Sato B; Kasayama S; Tachibana I
Intern Med; 2020 Feb; 59(4):569-572. PubMed ID: 31666468
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy-induced colitis: Could it be ulcerative colitis?
Moreno Moraleda I; Lázaro Sáez M; Diéguez Castillo C; Hernández Martínez Á
Gastroenterol Hepatol; 2021 Jan; 44(1):28-29. PubMed ID: 32873419
[No Abstract] [Full Text] [Related]
13. Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: A case report.
Muto Y; Namikawa K; Fujiwara Y; Mori T; Nakano E; Takahashi A; Yamazaki N
J Dermatol; 2020 Jan; 47(1):e9-e11. PubMed ID: 31674068
[No Abstract] [Full Text] [Related]
14. Management of immunotherapy colitis: Special considerations in the COVID-19 era.
Grover S; Bond SA; Mansour MK; Friedman S
Cancer; 2020 Nov; 126(21):4630-4633. PubMed ID: 32797685
[TBL] [Abstract][Full Text] [Related]
15. Advanced non-small cell lung cancer - treatment with Pembrolizumab.
Silvinato A; Floriano I; Bernardo WM
Rev Assoc Med Bras (1992); 2020 Mar; 66(3):256. PubMed ID: 32520141
[No Abstract] [Full Text] [Related]
16. Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma.
Oki R; Hirakawa Y; Kimura H; Honda K; Hinata M; Abe H; Domoto Y; Tanaka G; Nagase T; Nangaku M
Intern Med; 2020 Apr; 59(7):977-981. PubMed ID: 31813918
[TBL] [Abstract][Full Text] [Related]
17. Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab.
Basnet S; Dhital R; Tharu B
Medicina (Kaunas); 2019 May; 55(5):. PubMed ID: 31117208
[TBL] [Abstract][Full Text] [Related]
18. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
[TBL] [Abstract][Full Text] [Related]
19. Esophagitis in Non-Small Cell Lung Carcinoma Treatment Caused by Pembrolizumab.
Yoshida S; Miyamoto S; Naruse H; Ito J; Kinosita K; Kudo T; Hatanaka K; Yamamoto Y; Sakamoto N
Am J Gastroenterol; 2020 Jan; 115(1):13. PubMed ID: 31356230
[No Abstract] [Full Text] [Related]
20. Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer.
Wang H; Zhang L; Liu W
J Thorac Oncol; 2019 Jul; 14(7):e141-e143. PubMed ID: 31235036
[No Abstract] [Full Text] [Related]
[Next] [New Search]
